Loading organizations...
§ Private Profile · London, United Kingdom
Clinical-stage biotech developing IgE, IgA, IgG antibody therapeutics for cancer, including first IgE therapeutic in trials.
Epsilogen is a clinical-stage biotechnology company that develops proprietary antibody therapeutics for the treatment of solid tumors. The organization focuses on utilizing immunoglobulin IgE, IgA, and IgG isotypes, matching specific antibody attributes to targeted cancers or combining them into single molecules for enhanced therapeutic potency. Its lead clinical candidate, MOv18 IgE, targets folate receptor alpha in platinum-resistant ovarian cancer and represents the world's first IgE therapeutic to enter human clinical trials. The company has successfully completed a Phase I trial demonstrating safety and early clinical activity, and it is currently advancing the asset through a Phase Ib study. Epsilogen is backed by venture capital investors including the Novartis Venture Fund, while also establishing preclinical proof-of-concept for its proprietary IgEG platform. The company's founding year and original founders have not been publicly disclosed at this time.
Epsilogen has raised $63.0M across 3 funding rounds.
Epsilogen has raised $63.0M in total across 3 funding rounds.
Epsilogen has raised $63.0M across 3 funding rounds. Most recently, it raised $16.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $16M Series B | — | Marianne Bjørdal, 3B Future Health Ventures (helsinn Investment Fund), Albion VC, Novartis Venture Fund | Announced |
| Mar 1, 2022 | $41M Series B | Novartis Venture Fund | Marianne Bjørdal, 3B Future Health Ventures (helsinn Investment Fund), Albion VC | Announced |
| Nov 1, 2018 | $6M Series A | — | 20VC, Albion VC, Core Innnovation Capital, DFJ, Global Founders Capital, Nexus Venture Partners, Pear VC, Stride VC, ULU Ventures, Akshay Kothari, Girish Mathrubootham, Thomas Noonan | Announced |
Epsilogen is a clinical-stage biotechnology company pioneering the development of immunoglobulin E (IgE) antibody therapeutics for cancer treatment. Their lead product, MOv18 IgE, is the world’s first therapeutic IgE antibody to enter clinical trials, targeting folate receptor alpha-positive ovarian cancer. Epsilogen leverages the unique biological properties of IgE—such as enhanced potency, superior tumor penetration, and long tissue half-life—to develop novel cancer therapies that stimulate immune responses more effectively than traditional antibody treatments. The company also develops innovative antibody formats combining IgE and IgG isotypes to enhance therapeutic performance.
Epsilogen serves oncology patients, particularly those with solid tumors resistant to conventional therapies, addressing the unmet need for more effective immunotherapies. Their clinical progress, including successful Phase I trials demonstrating safety and early signs of efficacy, alongside ongoing Phase Ib studies, reflects strong growth momentum supported by significant venture capital backing and proprietary technology platforms.
Founded in 2017 as a spin-out from King’s College London, Epsilogen was established by scientists with deep expertise in antibody engineering and immunology. The idea emerged from recognizing the untapped potential of IgE antibodies, which naturally evolved to combat parasites, as powerful agents against solid tumors. Early pivotal moments include the successful development and clinical entry of MOv18 IgE, marking the first time an IgE therapeutic reached human trials, and the achievement of large-scale GMP manufacturing of IgE antibodies—an industry first.
The company has since evolved its focus from a single IgE candidate to a broader pipeline including IgE bispecifics and IgE/IgG combination antibodies (IgEGs), supported by multiple rounds of venture financing from prominent investors such as Novartis Venture Fund, Epidarex Capital, and British Patient Capital.
Epsilogen is riding the wave of immuno-oncology innovation, particularly the trend toward novel antibody isotypes and engineered immune therapies beyond traditional IgG monoclonal antibodies. The timing is critical as the oncology field seeks more potent and durable treatments for solid tumors, which remain challenging for existing immunotherapies. Market forces such as increasing cancer incidence, demand for personalized medicine, and advances in antibody engineering favor Epsilogen’s approach.
By pioneering IgE-based therapeutics, Epsilogen influences the broader ecosystem by expanding the antibody therapeutic landscape, encouraging exploration of alternative isotypes, and potentially setting new standards for antibody drug design and manufacturing.
Looking ahead, Epsilogen is poised to advance MOv18 IgE through later-stage clinical trials and further validate its IgE platform with additional pipeline candidates. Trends shaping their journey include growing acceptance of novel immunoglobulin isotypes in oncology, advances in bispecific and multi-isotype antibody engineering, and increasing collaboration between biotech and pharma sectors.
Epsilogen’s influence may evolve from a niche innovator to a leader in pan-isotype antibody therapeutics, potentially transforming cancer treatment paradigms by offering more effective and versatile immunotherapies. Their progress exemplifies how deep scientific insight combined with strategic development can unlock new frontiers in cancer care.
Epsilogen has raised $63.0M in total across 3 funding rounds.
Epsilogen's investors include Marianne Bjørdal, 3B Future Health Ventures (Helsinn Investment Fund), Albion VC, Novartis Venture Fund, 20VC, Core Innnovation Capital, DFJ, Global Founders Capital, Nexus Venture Partners, Pear VC, Stride VC, Ulu Ventures.